AI-drug-discovery platform bet with one program near a registrational inflection, contingent on FDA defining an approvable path from single-arm Phase 2 data

Bull

A positive outcome would show durable, deepening polyp burden reductions in the adult expansion cohort (18+) that replicate or exceed the 53% median reduction at Week 25 seen in the initial cohort, with a maintained Grade 1-2 safety profile and no new signals. This would give the FDA a compelling single-arm efficacy and safety package, enabling agreement on a registrational study design and positioning REC-4881 as the first approved medical therapy for FAP — a transformative outcome that validates the AI-drug-discovery platform thesis.

Bear

The most likely failure modes are attenuated or heterogeneous polyp burden reductions in the broader adult population relative to the initial cohort, or emergence of Grade 3-4 treatment-related adverse events at rates that complicate the benefit-risk argument for a non-life-threatening prophylactic indication. A second critical risk is FDA declining to accept single-arm Phase 2 data as registrational-grade evidence, requiring a randomized controlled trial and materially extending the timeline to approval, undermining the near-term inflection the thesis depends on.